Amgen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Amgen sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).
Amgen: 558 sponsored US clinical trials, 55 recruiting.
Amgen sponsors 558 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 373 completed. 212 of these trials are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 8 trials.
Top-decile sponsor footprint
Amgen ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
373 of 461 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
558 total, page 9 of 12
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
NCT01763827
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
NCT01752907
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
NCT01763866
Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
NCT01744782
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
NCT01696396
Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis
NCT01694485
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
NCT01732770
NOLAN: Naproxen or Loratadine and Neulasta
NCT01712009
Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects
NCT01755442
Osteonecrosis of the Jaw (ONJ) Case Registry
NCT01666106
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
NCT01690299
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT01697072
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
NCT01737879
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
NCT01666977
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
NCT01652872
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
NCT01677858
AMG 386 Drug-Drug Interaction Study With Paclitaxel
NCT01992341
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
NCT01439867
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
NCT01568866
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
NCT01624142
Safety Study of AMG 557 in Subjects With Lupus Arthritis
NCT01683695
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
NCT01345019
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
NCT01631214
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
NCT01583374
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
NCT01568229
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
NCT01568216
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
NCT01588496
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
NCT01544114
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
NCT01563185
Transition From Alendronate to Romosozumab (AMG 785)
NCT01588509
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
NCT01575873
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
NCT01575834
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
NCT01561963
Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults
NCT01634178
Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults
NCT01634191
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
NCT01543204
AMG 595 First-in-Human in Recurrent Gliomas
NCT01475006
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
NCT01516879
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01444417
AMG 172 First in Human Study in Patients With Kidney Cancer
NCT01497821
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
NCT01493505
AMG 761 in Adults With Asthma
NCT01514981
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
NCT01464931
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
NCT01493518
Single Ascending Dose Trial in Patients With Type 2 Diabetes
NCT01492465
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
NCT01416428
Open Label Study of Long Term Evaluation Against LDL-C Trial
NCT01439880
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
NCT01380756
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
NCT01389895
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
NCT01331941
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 216 |
| Phase 2 | 111 |
| Phase 3 | 174 |
| Phase 4 | 38 |
What is open in the Amgen pipeline
55 recruiting of 558 indexed (10% open); 373 completed (67%).
Phase mix: 212 late (III/IV) vs 327 early (I/II) (early-phase heavy).
Top condition: Obesity (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Amgen: open-pipeline peers nationwide
Peers matched on 558 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Amgen sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 558 trials (± recruiting share)
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Ohio State University · 552 trials · 21% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Ohio University · 10% recruiting · 51 trials
- Purdue University · 10% recruiting · 141 trials
- University of North Carolina, Chapel Hill · 10% recruiting · 1,109 trials
- Abiomed · 10% recruiting · 20 trials
Related
What to do with this Amgen page
558 registered trials is a research-attention snapshot, not an endorsement of Amgen or any single study.
- 55 of Amgen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Amgen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Amgen pipeline card: 558 registered trials from official public datasets.Report a data error.